MODIFIABLE RISK FACTORS FOR ADVERSE OUTCOMES IN SLE

本研究的目的是前瞻性地证实先前研究的系统性红斑狼疮（SLE）不良结局的风险因素。 可改变的风险因素已被证明会影响疾病活动，如SLAM所测量的，以及SF 36评估的SLE健康状况。 我们的目的是证实潜在的可改变的风险因素，如自我效能和社会支持确实影响疾病活动（SLAM）和健康状况（SF 36）。 心血管疾病导致SLE年轻女性发病率和死亡率过高。 我们计划研究SLE患者心血管危险因素管理（根据已发表的指南进行危险因素检测和适当管理）的变化。 我们还计划研究心血管风险因素管理、SLE特异性因素、社会人口学和心理社会因素与以下因素之间的关联：a）中间结局，包括吸烟、高血压、高脂血症、久坐不动的生活方式、肥胖和糖尿病;和B）心血管事件，包括心绞痛、心肌梗死、充血性心力衰竭和卒中。这项研究的基本设计是对1989年至1994年间首次接受评估的40名患者进行前瞻性随访。 每位患者将被要求通过邮件填写一份调查问卷。 之后，受试者将前往诊所接受医生的疾病活动性评估（SLAM）。6个月后将使用SA-SLAM测量疾病活动度，并通过SF 36测量身心健康。 这将通过邮件填写，对于非应答者，将通过电话或家庭访视进行随访。 将要求受试者自诊断狼疮以来，以及诊断前的相关问题，从所有提供者和医院发布有关其护理的所有医疗记录。 将审查记录中的心血管风险因素。

The objective of this investigation is to prospectively confirm previously examined risk factors for adverse outcomes in Systemic Lupus Erythematosus (SLE). Modifiable risk factors have been shown to impact on both the disease activity, as measured by the SLAM as well as health status assessed by SF 36 in SLE. We aim to confirm that potentially modifiable risk factors such as self-efficacy and social support do effect disease activity (SLAM) and health status (SF36). Cardiovascular disease results in excess morbidity and mortality in young women with SLE. We plan to study the variation in cardiovascular risk factor management (risk factor detection and appropriateness of management according to published guidelines) in patients with SLE. We also plan to look at the association between cardiovascular risk factor management, SLE-specific factors, socio-demographic and psychosocial factors and : a) intermediate outcomes including smoking, hypertension, hyperlipidemia, sedentary lifestyle, obesity and diabetes; and b) cardiovascular events including angina, myocardial infarction, congestive heart failure and stroke. The basic design of the proposed study is a prospective follow-up of 40 patients who were first evaluated between 1989 and 1994. Each patient will be asked to fill out a questionnaire by mail. After this subjects will come to the clinic for a physician assessment of disease activity (SLAM). Disease activity will be measured 6 months later using the SA-SLAM and physical and mental health will be measured by the SF36. This will be filled out by mail with telephone or home visit follow-up for non-respondents. Subjects will be asked to release all medical records regarding their care from all providers and hospitals since their diagnosis of lupus, and for relevant problems prior to diagnosis. The records will be reviewed for cardiovascular risk factors.